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Objective: Malignant pleural mesothelioma is resistant to conventional therapies and
to apoptosis. The bcl-2 family genes are major determinants of apoptotic homeosta-
sis. Malignant pleural mesothelioma lines and tumors rarely express the antiapop-
totic Bcl-2 protein but routinely express the antiapoptotic protein Bcl-xl and the
proapoptotic proteins Bax and Bak. We have previously shown pharmacologic
inhibition of bcl-xl expression in malignant pleural mesothelioma can lead to
apoptosis, so we sought to determine whether antisense oligonucleotides directed at
bcl-xl messenger RNA would engender apoptosis, possibly through a “forced
imbalance” of bcl-2 family proteins.
Methods: Malignant pleural mesothelioma lines REN (epithelial) and I-45 (sarco-
matous) were exposed to modified bcl-xl antissense oligonecleotides directed near
the messenger RNA initiation sequence with and without a liposomal delivery
system. Untreated cells and bcl-xl sense oligonucleotides were controls. Cell via-
bility was measured by colorimetric assay, and apoptosis was evaluated with
Hoechst staining and sub-G1 fluorescence-activated cell sorter analysis.
Results: Bcl-xl protein expression after antisense oligonucleotides was downwardly
regulated in both cell lines relative to sense oligonucleotides (65%). Significant
cellular killing in both the I-45 and REN cell lines was achieved with antisense
oligonucleotides (compared with sense oligonucleotides) without (P  .003 and
.006, respectively) and with (P  .006 and .0005, respectively) liposomal delivery.
Hoechst staining and sub-G1 fluorescence-activated cell sorter analysis demon-
strated apoptosis to be the mechanism of cellular death. Use of a liposomal delivery
system increased therapeutic effect and allowed lower doses of antisense oligonu-
cleotides.
Conclusion: Antisense oligonucleotides directed at the bcl-xl gene product engender
apoptosis in mesothelioma cell lines. The therapeutic potential of inhibiting expres-
sion of this protein in mesothelioma should be evaluated.
Malignant pleural mesothelioma (MPM) continues to be a dif-ficult clinical problem with a high case/fatality ratio. Ad-vances in staging, evaluation, and histopathology have iden-tified a highly selected subgroup that might benefit fromaggressive multimodality therapy, but the prognosis for allpatients with this disease remains poor.1,2 This tumor is
clinically resistant to conventional chemotherapy, with no regimen consistently
demonstrating a response greater than 20% and most trials demonstrating no
significant benefit.3-5 This is especially discouraging if one considers the fact that
metastatic disease (once thought rare) has been noted with increasing frequency as
local control measures have improved.6,7 Failure of conventional treatment has led
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to an interest in novel approaches, such as prodrug gene
therapy with the herpes simplex virus thymidine kinase-
ganciclovir system and immunotherapy.8-10
Another novel approach being explored in cancer treat-
ment, although little studied for MPM, is the forced induc-
tion of programmed cell death, or apoptosis. Although the
discrete mechanisms of action vary, many conventional
treatments depend on an ability to engender apoptosis as a
final common pathway. We have previously shown that the
specific downward regulation of expression of the bcl-xl
gene product at both the protein and messenger RNA
(mRNA) levels by exposure to a histone deacetylase inhib-
itor, sodium butyrate, can lead to the development of apo-
ptosis in MPM cells.11 We have also demonstrated that this
decrease in bcl-xl expression can prime MPM cells for a
second proapoptotic stimulus, such as adenoviral transfer of
the genes coding for the proapoptotic proteins Bak and
Bax.12,13 Although seemingly specific for this member of
the bcl-2 family, it is certain that the expression of a number
of other genes would be affected by a pharmacologic treat-
ment such as sodium butyrate that inhibits histone deacety-
lase and allows more accessible compelementary DNA for
transcription. This raises the question as to whether these
previous findings represent a true cause and effect for in-
duction of apoptosis in MPM cell lines or epiphenomena
related to other unknown genetic events induced by butyrate
exposure. To evaluate this question and elucidate means by
which this reproducible finding of Bcl-2 protein family
expression can be capitalized on therapeutically, it will be
necessary to develop a more specific method to downwardly
regulate bcl-xl gene expression. In this study we evaluated
the ability of an antisense oligonucleotide construct directed
near the region of the translation initiation site for the bcl-xl
messenger RNA to specifically downwardly regulate ex-
pression of Bcl-xl protein and lead to apoptotic cellular
death in human MPM tumor cell lines.
Methods
Cell Lines and Growth Conditions
To study the effect of bcl-xl antisense oligonucleotide exposure in
MPM, two well-characterized cell lines were used, I-45 and REN.
I-45 is a human sarcomatous type MPM, p53 wild-type (donated
generously by Dr Joseph Testa of the Fox Chase Institute, Phila-
delphia, Pa). REN is a human epithelial type MPM and p53 mutant
(developed by author W.R.S.).14 Cell lines were maintained in
Roswell Park Memorial Institute medium containing 10% (vol-
ume/volume) fetal bovine serum, 1% nonessential amino acids,
and 100-g/mL penicillin and 100-g/mL streptomycin. Cells
were housed in a humidified incubator with 5% carbon dioxide at
37°C.
Antisense Oligonucleotide Constructs and in Vitro
Transfection Methods
High-performance liquid chromatography-purified 20-mer bcl-x
antisense oligonucleotides and complementary-sense oligonucleo-
tides were designed and synthesized (Life Technologies, Inc,
Rockville, Md). The antisense oligonucleotide sequence matches
the translation-initiation site of human bcl-x presplice mRNA. The
oligonucleotides were designed with a 2-o-(2-methoxy) ethyl
modification to assist in prevention of cellular and extracellular
enzymatic degradation. The bcl-x antisense sequence was as fol-
lows: 5-CCC GGT TGC TCT GAG ACA TT-3. The bcl-x sense
sequence was as follows: 5-AAT GTC TCA GAG CAA CCG
GG-3.
Western Blot Analysis
After MPM cells were exposed to oligonucleotides or control
vehicle and cultured for 24, 48, or 72 hours, total cell lysates were
prepared by lysing plated cell monolayers with sodium dodecyl-
sulfate-polyacrylamide gel electrophoresis sample buffer. The pro-
tein content of the lysates was then determined by BCA protein
assay (Pierce, Rockford, IL). Then, each lane on a sodium dode-
cylsulfate-polyacrylamide (12%) gel was loaded with 20 g of cell
lysate and electrophoresed to separate proteins under reducing
conditions for the protein of interest. After electrophoresis at 20
mA for 2 hours, the proteins were transferred to high-bond ECL
membranes (Amersham Corp, Arlington Heights, Ill). The mem-
branes were then incubated with the primary and secondary anti-
bodies and developed according to the Amersham ECL protocol.
Actin was used as a control. Antibodies to actin and Bcl-xl were
obtained from Santa Cruz Biotechnology, Inc, Santa Cruz, Calif.
Cellular Viability Assay
Cell viability was tested with the XTT colorimetric assay system
(Sigma, St Louis, Mo). After REN and I-45 exposures to oligo-
nucleotides or control at varying doses, the assay evaluated sur-
viving cells at 48 hours after dosing. The labeling reagent was
added to the electron-coupling reagent (Roche Diagnostics GmbH,
Mannheim, Germany) in a 1:50 ratio. A 50-L aliquot of this XTT
mixture was then added to each well in a 96-well plate. Plates were
than incubated at 37°C for 4 hours. The plates were then analyzed
with a colorimetric microplate reader at a wavelength of 450 nm.
(DYNEX Technologies, Inc, Chantilly, Va).
Apoptosis Assays
Apoptotic cell death was evaluated by changes in cell morphologic
and flow cytometric characteristics. Fluorescence-activated cell
sorter analysis was performed as follows: after oligonucleotide
exposure and 48-hour culture, cells were trypsin digested, col-
lected by centrifugation, resuspended in Phosphate-buffered saline
solution, and fixed in 70% ethanol at 4°C for 1 hour. After
centrifugation, the cells were washed in phosphate-buffered saline
solution and resuspended in PI staining solution (Roche Diagnos-
tics Corporation, Laboratory Systems, Indianapolis, Ind). Speci-
mens were incubated in the dark for 30 minutes at 37°C and then
analyzed with the use of an EPICS Profile II flow cytometer
(Coulter Corporation, Hialeah, Fla). An analysis region was set on
the basis of the negative controls, and the percentage of sub-G1
cells was calculated from this region. For Hoechst staining, cells
were plated in chamber slides at a concentration of 5000 cells in
500 L medium. After 24 hours, the cells were exposed to oligo-
nucleotides. After 72 hours, cells were washed with phosphate-
buffered saline solution and then fixed with acetone and acetic acid
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(3:1). After fixation, Hoechst nuclear staining solution (0.1 g/
mL) was added. Nuclei were than examined with a fluorescent
microscope (Nikon Diaphou; Nikon Inc, Melville, NY). Apoptosis
was characterized as cells with large segmented nuclei.
Results
Inhibition of Mesothelioma Expression of Bcl-xl
Protein by Antisense Oligonucleotide Exposure
Before commenting on the effects of bcl-xl antisense oligo-
nucleotide exposure, it is first necessary to demonstrate that
the intended effect on the gene product (in this case down-
ward regulation of Bcl-xl protein expression) is noted after
exposure. To demonstrate more rigorously whether the
bcl-xl antisense oligonucleotide is effective in this regard, a
comparison was made between Bcl-xl protein expressions
following REN and I-45 exposures to antisense oligonucle-
otide and sense oligonucleotide, rather than to baseline (no
oligonucleotide), to assess any effect of nonspecific sense
oligonucleotide toxicity on protein production. As is noted
in Figure 1, significant decreases in bcl-xl expression were
noted in REN and I-45 cells after exposure to bcl-xl anti-
sense oligonucleotide relative to bcl-xl sense oligonucleo-
tide exposure. According to quantitative densitometry,
Bcl-xl expression was decreased by 78% in REN (22% of
control) and 67% in I-45 (33% of control) cell lines. No
effect on actin protein expression was noted.
Mesothelioma Cellular Death After Exposure to bcl-xl
Antisense Oligonucleotides, Intensified by Liposomal
Transfer
A colorimetric (XTT) assay was performed to compare the
effects of bcl-xl antisense oligonucleotide and sense oligo-
nucleotide exposures on cellular viability in both MPM cell
lines. Figure 2, A and B, shows the dose-response effects of
exposures to bcl-xl antisense oligonucleotide and sense
oligonucleotides alone (no liposomes). In the REN and I-45
cell lines, approximately 40% and 50% of cells, respec-
tively, were killed by exposure to antisense oligonucleotide
at the highest dose without liposomes (200 mol/L), and in
both cases the difference of effect between sense and anti-
sense oligonucleotide exposures was significant (200
mol/L, REN P  .006; I-45 P  .003, by analysis of
variance [ANOVA]). Little overall effect was noted on
cellular viability after sense oligonucleotide exposure in
either cell line. We then evaluated the effect of bcl-xl
antisense oligonucleotide and sense oligonucleotide transfer
on REN and I-45 cellular viability in a similar fashion as
previously, with the use of a commercially available lipo-
somal delivery system (Oligofectamine; Invitrogen Corpo-
ration, Carlsbad, Calif), and the results are demonstrated in
Figure 3, A and B. There was a significant effect of antisense
oligonucleotide treatment and a significant difference noted
between bcl-xl antisense oligonucleotide and sense oligo-
nucleotide treatments at much lower doses of oligonucleo-
tide, with approximately 60% of REN and 90% of I-45 cells
affected (100 nmol/L, REN P  .0005, I-45 P  .006, by
ANOVA). Nonspecific liposomal toxicity effect on cellular
viability was noted, with more than 20% of cells killed by
the sense oligonucleotide-liposome combination in both
REN and I-45 cells.
Apoptosis as the Mechanism for Cellular Death in
Mesothelioma Cells Exposed to Antisense
Oligonucleotides
To determine whether the cellular death noted previously
was due to apoptosis rather than other causes, morphologic
and DNA content analyses for apoptosis were then per-
formed. According to Hoechst staining, a significant popu-
lation of MPM cells exposed to bcl-xl antisense oligonucle-
otide demonstrated fragmentation consistent with apoptosis
(data not shown). In an effort to more objectively quantify
apoptosis, fluorescence-activated cell sorter cell cycle anal-
ysis was performed, evaluating the percentage of cells in
sub-G1 phase after antisense oligonucleotide and sense oli-
gonucleotide exposures with and without liposomal delivery
Figure 1. Western blot analysis of Bcl-xl protein expression after exposure to bcl-xl antisense (ASO) and sense
(SO) oligonucleotide constructs. Comparative densitometry demonstrates relative reductiond of Bcl-xl protein of
67% in I-45 and 78% in REN cell lines. Actin expression is shown as control and was unaffected by differential
treatment.
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systems. Figure 4 demonstrates that apoptosis was present,
increased with antisense oligonucleotide relative to sense
oligonucleotide, and accentuated with liposomal antisense
oligonucleotide transfer.
Discussion
Antisense oligonucleotides have been in use since the late
1970s. Zamencik and colleagues15 introduced the idea of
therapeutic antisense oligonucleotides to prevent neoplastic
transformation of cells exposed to the Rous sarcoma virus.15
These short sequences of nucleotides, generally between 13
and 20 base pairs in length, are constructed to base pair with
a specific mRNA sequence of a gene product of interest. By
means of one of a number of mechanisms proposed (endo-
nuclease digestion, triplex formation, translational arrest,
and others), this base pairing of the oligonucleotide and the
mRNA of interest leads to a relatively specific decrease in
the expression of the desired protein.16 Initial enthusiasm
regarding this approach was tempered somewhat in the
early 1990s by the perception that in vitro results could not
Figure 2. Cell viability assay (XTT) of mesothelioma cell lines after bcl-xl antisense (filled squares) and sense (open
squares) oligonucleotide exposures. A, Assay data for REN cell line demonstrating approximately 40% of cells
killed by bcl-xl antisense oligonucleotide exposure, with little effect noted after bcl-xl sense oligonucleotide
exposure (P .006 at 200 mol/L by ANOVA). B, Assay data for I-45 cell line line demonstrating approximately 50%
of cells killed by bcl-xl antisense oligonucleotide exposure, with little effect noted after bcl-xl sense oligonu-
cleotide exposure (P  .003 at mol/L by ANOVA).
Figure 3. Cell viability assay (XTT) of mesothelioma cell lines after bcl-xl antisense (filled squares) and sense (open
squares) oligonucleotide exposures with a liposomal delivery system. A, Assay data for REN cell line demon-
strating approximately 60% of cells killed by bcl-xl antisense oligonucleotide exposure, with approximately 20%
of cells killed after bcl-xl sense oligonucleotide exposure (P  .0005 at 100 nmol/L by ANOVA). B, Assay data for
I-45 cell line demonstrating approximately 90% of cells killed by bcl-xl antisense oligonucleotide exposure, with
approximately 30% of cells killed after bcl-xl sense oligonucleotide exposure (P  .006 at 100 nmol/L by ANOVA).
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easily be translated in vivo into animal models and human
treatments for various diseases because of delivery and
toxicity issues.17 However, more appropriate targets have
now been identified, further modifications of backbone
structure have been realized, and delivery methods have
been improved.18 In addition to past and ongoing evaluation
of antisense oligonucleotides in the laboratory, a number of
clinical trials with antisense oligonucleotides have been
completed for malignant diseases, with efficacy noted in
phase I and phase I-II trials for leukemia (c-myb targeting),
lymphoma (bcl-2 targeting), and melanoma (bcl-2 targeting
combined with chemotherapy).19-21 More effective targets
that may be generated by current efforts in both genomics
and proteomics, further refinements in delivery techniques,
and alternative constructs such as ribozymes and deoxyri-
bozymes promise to make this strategy more tenable in the
future as a means of treating malignant disease.22
The attraction of the bcl-2 family of genes and gene
products for treatment lies in the fact that these proteins help
to control one of the final common pathways for a variety of
apoptotic stimuli, namely the release of cytochrome c from
the mitochondrial membrane and activation of caspases.23
The Bcl-2 family is a group of more than 15 proteins that,
through relationships with one another as well as other
constituents of programmed cell death pathways, regulate
apoptotic homeostasis in cells. The longer splice product of
the bcl-x gene (located on the short arm of chromosome 20;
20pter-p12.1), Bcl-xl, is one of the more important anti-
apoptotic members of this family. Like Bcl-2, this protein
seems to function on a basic level as an ion-type channel
regulator of mitochondrial membrane stability.24 The Bcl-xl
protein has been shown to bind directly to the porin voltage-
dependent ion channel protein and to prevent cytochrome c
release from the mitochondrion, even after proapoptotic
stimuli.25 Unlike Bcl-2, it does not seem to require dimer-
ization with proapoptotic proteins such as Bax to provide
apoptosis prevention, although it can interact with a number
of these proteins, including Bax, Bak, and Bad.26 It has been
demonstrated that Bcl-xl is at least as potent as Bcl-2 in the
prevention of apoptosis in a wide variety of human malig-
nant cell lines when challenged with cytotoxic and proapop-
totic stimuli.27 Interestingly, Bcl-xl appears to be much
more important developmentally in mammals, because bcl-
x-deficient mice undergo massive central neural and hema-
topoietic apoptosis, with resultant embryonic death,
whereas bcl-2-deficient strains survive.28
Several investigators have noted a consistent alteration
of Bcl-2 family expression pattern in MPM. Narasimhan
and associates29 noted that Bcl-2 expression was absent in
13 of 17 MPM cell lines and present only during mitosis in
the 3 of 17 that did have positive results. In this same study,
Bax expression was uniform in all lines. Similarly, Segers
and colleagues30 noted a lack of expression of Bcl-2 in 57 of
62 MPM tumor specimens, and Soini and coworkers31 dem-
onstrated that 7 of 7 MPM cell lines and 28 of 35 tumor
specimens lacked expression of Bcl-2, although in all lines
and tumors Bcl-xl expression was intact. The findings that
expression of only one of these antiapoptotic proteins is
common (Bcl-2 rare, Bcl-xl common) and that expressions
of all major proapoptotic proteins, such as Bax and Bak, are
Figure 4. Sub-G1 fluorescence-activated cell sorter analysis after bcl-xl antisense and sense oligonucleotide
exposures in I-45 mesothelioma cell line. Level of apoptosis was increased with antisense oligonucleotide
treatment and was accentuated when liposomal delivery system (filled bars) was used.
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intact may indicate a potential therapeutic target—down-
ward regulation of expression of bcl-xl with resultant “un-
opposed” proapoptotic protein expression.
Our previous work has suggested a critical role for bcl-xl
gene expression in MPM cell lines with respect to apoptotic
maintenance. We have demonstrated that pharmacologic
downward regulation of bcl-xl expression at both the pro-
tein and mRNA levels by a histone deacetylase inhibitor,
sodium butyrate, can lead to apoptotic cellular death. Sup-
porting these results is an experiment demonstrating that
when we caused overexpression of bcl-xl in MPM cells by
stable plasmid transfer that the sensitivity to butyrate was
abrogated, and this insensitivity was proportional to level of
Bcl-xl protein production.11 We theorize that the “forced
imbalance” of bcl-2 family proteins by Bcl-xl downward
regulation in this situation leads to relatively unapposed
proapoptotic protein expression and therefore ultimately to
apoptosis. In further support of this hypothesis, we have
shown that upward regulation of proapoptotic Bak protein
expression in these MPM cell lines by use of a binary
adenoviral gene therapy vector system may engender apop-
tosis, with other Bcl-2 family member levels of protein
expression unaffected.32 In earlier experiments we demon-
strated an apparently specific effect of sodium butyrate on a
single member of the Bcl-2 family in mesothelioma.11 The
obvious concern, however, in any experiment involving the
exposure of cells to pharmacologic agents is the effect on
genes or proteins that are not being evaluated. This concern
is compounded by the fact that sodium butyrate is a histone
deacetylase inhibitor. These agents actually inhibit the re-
winding of DNA onto histones when it is not actively being
transcribed and are therefore usually associated with up-
ward regulation of gene transciption rather than downward
regulation. To address these concerns, in this series of
experiments we sought to regulate bcl-xl gene expression
downward more specifically through antisense techniques
targeting the bcl-xl mRNA.
Other investigators have demonstrated the therapeutic
ability of antisense oligonucleotides directed at the bcl-xl
gene product. Leech and coworkers,33 demonstrated the
ability of modified bcl-xl antisense oligonucleotides to in-
duce apoptosis in lung cancer cell lines. However, this was
effective only in lines lacking bcl-2 expression and was
ineffective in lines expressing both Bcl-xl and Bcl-2 (cogent
to the situation with MPM cells and tumors). This group
later demonstrated that a bispecific bcl-2/bcl-xl antisense
oligonucleotide was necessary to engender apoptosis in
tumor cell lines expressing both proteins.34 Overexpression
of bcl-xl has been noted as well in breast carcinoma and in
gastric carcinoma (with absence of Bcl-2 protein expres-
sion), and again apoptotic cellular death has been engen-
dered by exposure to a bcl-xl antisense oligonucleotide.35,36
The finding that the bcl-xl antisense oligonucleotide con-
struct used here was more effective at a lower dose when
combined with a liposomal transfer system is not surprising.
Lipsomal delivery systems have been known for quite some
time to enhance cellular uptake of oligonucleotides in vitro,
especially those that are cationic.18,37 Although antisense
oligonucleotides have been known for quite some time to be
effective inhibitors of specific mRNA products, an adeno-
viral vector capable of transferring the antisense construct
could be considered as an alternative and would give addi-
tional assurance of cellular entry. An adenoviral vector
paradigm could have certain other advantages as well, in-
cluding avoidance of lysosomal degradation and greatly
increased copy number of the antisense construct. Various
constructs have been used both in vitro and in vivo to treat
non-small-cell lung cancer (anti-K-ras), gastric carcinoma
(anti-endothelial growth factor receptor), glioma (anti-
urokinase type plasminogen activator), and small cell lung
carcinoma (anti-c-kit).38-41
What about the clinical application of bcl-xl antisense
oligonucleotides to the treatment of this disease? As has
been noted with a variety of gene therapy techniques, com-
bination therapies with conventional modalities plus anti-
sense may be necessary. We have noted previously that
pharmacologic inhibition of bcl-xl could prime MPM cells
for a second proapoptotic stimulus (proapoptotic gene trans-
fer of the bak or bax gene).12,13 Other investigators have
noted a relationship between Bcl-xl expression and chemo-
therapy sensitivity. In one study, U-937 cells were stably
transfected to overexpress Bcl-xl, and apoptosis was de-
creased after exposure to vinblastine, paclitaxel, and cispla-
tin by 67%, 51%, and 55%, respectively.42 In a system
designed to provide lymphoma cells with microenvironment
survival adjuvants (CD40 antibody, interleukin 4, vascular
cell adhesion molecule 1 fusion protein) followed by eto-
poside, the most consistent change that correlated with
chemotherapy resistance was upward regulation of Bcl-xl
expression. Expected downward regulation of proapoptotic
proteins Bak and Bax were not noted.43 Similarly, Luo and
associates44 demonstrated that hepatoblastoma cells were
rendered more sensitive to paclitexel and doxorubicin by
stable transfection of a bcl-xl antisense construct. When
colonic adenocarcinoma cells noted be deficient in Bcl-2 but
to overexpress Bcl-xl were treated with bcl-xl antisense
oligonucleotides followed by 5-fluorouracil, they exhibited
a 40% decrease in cell viability and a 55% increase in
apoptosis relative to 5-fluorouracil alone.45 Finally, stable
bcl-xl overexpression in a murine tumor cell line (FK5.12)
has been shown to engender a form of multidrug resistance
phenotype, with these cells dramatically more resistant than
parental cells to a panel of six different chemotherapeutic
agents (bleomycin, vincristine, cisplatin, etoposide) and
metabolic poisons (hygromycin B, mycophenolate).46 We
are currently investigating the ability of this and other bcl-xl
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antisense constructs to act in an additive or synergistic
fashion with conventional chemotherapeutic agents in MPM
cells and with the transfer of proapoptotic genes. According
to our studies to date, bcl-xl expression appears to be a
viable target for therapeutic investigation in MPM, and
continued investigation is warranted.
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Discussion
Dr David S. Schrump (Bethesda, Md). I have several ques-
tions relating to duration of exposure, resistance, and so forth. I
looked at the growth inhibition assays, and there is a nice response.
It seems to be dose related. Have you looked at the minimum
duration that is required to achieve apoptosis? As a follow-up,
have you looked to see what happens to the cells that become
resistant to the antisense effect? Are you able to achieve 100%
killing if you modify the conditions? If not, what is the phenotype
of the cells that are resistant?
Dr Smythe. In answer to the first question, the cellular viability
effect and apoptosis both appear to peak somewhere between 24
and 48 hours. Beyond that time, exposure really does not do much
more. Actually, the cells will begin to regrow. With respect to the
phenotype or the genotype of the cells that are resistant to anti-
sense, we have not examined that.
Dr Schrump. Are the doses that you used comparable with
what has been achieved in the phase I studies?
Dr Smythe. Yes, they are comparable, especially with the
liposomal delivery system. Interestingly enough, of the two phase
I studies that have been reported, neither used a liposomal delivery
system. They just used oligonucleotide alone. But these doses are
definitely comparable.
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